Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts

Basic Research in Cardiology

Volumn 107, Issue 2, 2012, Pages

  Koka, Saisudha ^a   Xi, Lei ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac remodeling; Cytoskeletal proteins; Diabetes; Oxidative stress; Phosphodiesterase 5 inhibitors; Proteomics

Indexed keywords

COLLAGEN TYPE 4; COLLAGEN TYPE 4ALPHA; CYSTEINE; GLUCOSE REGULATED PROTEIN; GLUCOSE REGULATED PROTEIN 75; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE KAPPA1; GLYCINE RICH PROTEIN 3; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 8; INTERMEDIATE FILAMENT PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN ALPHA; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN 4; PHOSPHODIESTERASE V INHIBITOR; SCLEROPROTEIN; TADALAFIL; UNCLASSIFIED DRUG; VIMENTIN; CARBOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; ENZYME INHIBITION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; MASS SPECTROMETRY; PROTEOMICS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARBOLINES; CYTOSKELETON; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HEART; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; OXIDATION-REDUCTION; PHOSPHODIESTERASE 5 INHIBITORS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VENTRICULAR FUNCTION, LEFT;

EID: 84856451489     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0249-5     Document Type: Article

References (62)

1. Aasum E, Hafstad AD, Severson DL, Larsen TS (2003) Agedependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52:434-441. doi:10.2337/diabetes.52.2.434 (Pubitemid 36173200)
2. Bartnik M, Norhammar A, Ryden L (2007) Hyperglycaemia and cardiovascular disease. J Intern Med 262:145-156. doi: 10.1111/j.1365-2796.2007.01831.x (Pubitemid 47087633)
3. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, Wayman C, Alexandre L, Giuliano F (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47:87-91. doi:10.1016/j.eururo.2004.09.005 (Pubitemid 39575722)
4. Berria R, Wang L, Richardson DK, Finlayson J, Belfort R, Pratipanawatr T, De Filippis EA, Kashyap S, Mandarino LJ (2006) Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab 290:E560-E565. doi: 10.1152/ajpendo.00202.2005 (Pubitemid 43671704)
5. Bertoni AG, Tsai A, Kasper EK, Brancati FL (2003) Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26:2791-2795. doi:10.2337/diacare.26.10.2791 (Pubitemid 37205548)
6. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213-3223. doi:10.1161/CIRCULATIONAHA. 106.679597 (Pubitemid 47012236)
7. Brickson S, Fitzsimons DP, Pereira L, Hacker T, Valdivia H, Moss RL (2007) In vivo left ventricular functional capacity is compromised in cMyBP-C null mice. Am J Physiol Heart Circ Physiol 292:H1747-H1754. doi:10.1152/ ajpheart.01037.2006 (Pubitemid 46572397)
8. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955. doi:10.1074/jbc.M404706200
9. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJ, Taegtmeyer H (2000) Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 32:985-996. doi:10.1006/jmcc. 2000.1139 (Pubitemid 30663106)
10. Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239-247. doi:10.1016/S0008-6363(98)00186-2 (Pubitemid 28506032)
11. Dillmann WH (1982) Influence of thyroid hormone administration on myosin ATPase activity and myosin isoenzyme distribution in the heart of diabetic rats. Metabolism 31:199-204. doi: 10.1016/0026-0495(82)90052-x (Pubitemid 12176904)
12. Elrod JW, Greer JJ, Lefer DJ (2007) Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 292:H342-H347. doi:10.1152/ ajpheart.00306.2006 (Pubitemid 46105196)
13. Essop MF, Chan WA, Hattingh S (2011) Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes. Cardiovasc J Afr 22:175-178. doi:10.5830/CVJA-2010-058
14. Falcao-Pires I, Palladini G, Goncalves N, van der Velden J, Moreira-Goncalves D, Miranda-Silva D, Salinaro F, Paulus WJ, Niessen HWM, Perlini S, Leite-Moreira AF (2011) Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol 106:801-814. doi: 10.1007/s00395-011-0184-x
15. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610. doi:10.1161/01.CIR.0000160359.49478. C2 (Pubitemid 40525159)
16. Flashman E, Redwood C, Moolman-Smook J, Watkins H (2004) Cardiac myosin binding protein C: its role in physiology and disease. Circ Res 94:1279-1289. doi:10.1161/01.RES.00001271 75.21818.C2 (Pubitemid 38724473)
17. Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F (2011) Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3 beta signaling. Basic Res Cardiol 106:147-162. doi:10.1007/s00395-010-0130-3
18. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146. doi:10.1161/01.CIR.100.10.1134 (Pubitemid 29416243)
19. Hayat SA, Patel B, Khattar RS, Malik RA (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 107:539-557. doi:10.1042/CS20040057 (Pubitemid 39627201)
20. Honisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C (2010) Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATPchannel activation but is independent of PDE-III inhibition. Basic Res Cardiol 105:155-167. doi:10.1007/s00395-009-0064-9
21. Howarth FC, Qureshi MA, Hassan Z, Al Kury LT, Isaev D, Parekh K, Yammahi SR, Oz M, Adrian TE, Adeghate E (2011) Changing pattern of gene expression is associated with ventricular myocyte dysfunction and altered mechanisms of Ca2+ Signaling in young type 2 Zucker diabetic fatty rat heart. Exp Physiol 96:325-337. doi:10.1113/expphysiol.2010.055574
22. Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH (2010) Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 105:399-407. doi:10.1007/s00395- 009-0071-x
23. Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan GM, Bernardi P, Bonaldo P (2003) Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 35:367-371. doi:10.1038/ng1270 (Pubitemid 37486921)
24. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29-34. doi:10.1016/0002-9149(74)90089-7
25. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC (2010) Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 334:1023-1030. doi:10.1124/jpet.110.170191
26. Koka S, Kukreja RC (2010) Attenuation of doxorubicin-induced cardiotoxicity by tadalafil: a long acting phosphodiesterase-5 inhibitor. Mol Cell Pharmacol 2:173-178. doi:10.4255/ mcpharmacol.10.23
27. Kuan J, Brock G (2002) Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs 11:1605-1613. doi:10.1517/ 13543784.11.11.1605 (Pubitemid 35331493)
28. Kudlicki W, Coffman A, Kramer G, Hardesty B (1997) Renaturation of rhodanese by translational elongation factor (EF) Tu. Protein refolding by EF-Tu flexing. J Biol Chem 272: 32206-32210. doi:10.1074/jbc.272.51.32206 (Pubitemid 28011896)
29. Kudlicki W, Coffman A, Kramer G, Hardesty B (1997) Ribosomes and ribosomal RNA as chaperones for folding of proteins. Fold Des 2:101-108. doi:10.1016/S1359-0278(97)00014-x (Pubitemid 127740458)
30. Kukreja RC, Ockaili R, Salloum F, Xi L (2003) Sildenafilinduced cardioprotection in rabbits. Cardiovasc Res 60:700-701. doi:10.1016/j.cardiores. 2003.10.002 (Pubitemid 37501128)
31. Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E, Kass DA (2010) PDE5A suppression of acute betaadrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol 105:337-347. doi:10.1007/s00395-010-0084-5
32. Li QF, Spinelli AM, Tang DD (2009) Cdc42GAP, reactive oxygen species, and the vimentin network. Am J Physiol Cell Physiol 297:C299-C309. doi:10.1152/ajpcell.00037.2009
33. Li QF, Spinelli AM, Wang R, Anfinogenova Y, Singer HA, Tang DD (2006) Critical role of vimentin phosphorylation at Ser-56 by p21-activated kinase in vimentin cytoskeleton signaling. J Biol Chem 281:34716-34724. doi:10.1074/jbc.M607715200 (Pubitemid 46036677)
34. Liu X, Takeda N, Dhalla NS (1997) Myosin light-chain phosphorylation in diabetic cardiomyopathy in rats. Metabolism 46:71-75. doi:10.1016/S0026-0495(97) 90171-2 (Pubitemid 27052028)
35. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5:59-63. doi:10.1038/ncb898 (Pubitemid 36054330)
36. Nagy O, Hajnal A, Parratt JR, Vegh A (2004) Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 141:549-551. doi: 10.1038/sj.bjp.0705658 (Pubitemid 38453246)
37. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263-H1269. doi:10.1152/ajpheart.00324. 2002
38. Park Y, Yang JY, Zhang HR, Chen XN, Zhang CH (2011) Effect of PAR2 in regulating TNF-alpha and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice. Basic Res Cardiol 106:111-123. doi:10.1007/s00395-010-0129-9
39. Paulson DJ, Gupta M, Zak R, Zhao J (1992) Effects of exercise training and diabetes on cardiac myosin heavy chain composition. Mol Cell Biochem 117:175-179. doi:10.1016/0022-2828(91) 91548-6 (Pubitemid 23014294)
40. Richardson DK, Kashyap S, Bajaj M, Cusi K, Mandarino SJ, Finlayson J, DeFronzo RA, Jenkinson CP, Mandarino LJ (2005) Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 280:10290-10297. doi:10.1074/jbc.M408985200 (Pubitemid 40395885)
41. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M (2011) Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 106:249-262. doi:10.1007/ s00395-010-0138-8
42. Salloum F, Yin C, Xi L, Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthasedependent pathway in mouse heart. Circ Res 92:595-597. doi: 10.1161/01.RES.0000066853.09821.98 (Pubitemid 36417692)
43. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294:H1398-H1406. doi:10.1152/ajpheart. 91438.2007 (Pubitemid 351468739)
44. Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, Ockaili RA, Toldo S, Kukreja RC (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide. Circulation 120:S31-S36. doi:10.1161/CIRCULATION AHA.108.843979
45. Schlossarek S, Englmann DR, Sultan KR, Sauer M, Eschenhagen T, Carrier L (2012) Defective proteolytic systems in Mybpc3- targeted mice with cardiac hypertrophy. Basic Res Cardiol 107:1-13. doi:10.1007/s00395-011-0235-3
46. Sesti C, Florio V, Johnson EG, Kloner RA (2007) The phosphodiesterase- 5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 19:55-61. doi:10.1038/sj.ijir.3901497 (Pubitemid 46067349)
47. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM Jr, Klein JB, Epstein PN (2004) Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab 287:E896-E905. doi:10.1152/ajpendo. 00047.2004 (Pubitemid 39382925)
48. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs no causal role for risk activation. Circ Res 104:15-18. doi:10.1161/CIRCRESAHA.108.186429
49. Spector KS (1998) Diabetic cardiomyopathy. Clin Cardiol 21:885-887. doi:10.1002/clc.4960211205 (Pubitemid 28559694)
50. Stelzer JE, Brickson SL, Locher MR, Moss RL (2007) Role of myosin heavy chain composition in the stretch activation response of rat myocardium. J Physiol 579:161-173. doi: 10.1113/jphysiol.2006.119719
51. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222. doi:10.1038/nm1175 (Pubitemid 40321358)
52. Turko IV, Murad F (2003) Quantitative protein profiling in heart mitochondria from diabetic rats. J Biol Chem 278:35844-35849. doi:10.1074/jbc.M303139200 (Pubitemid 37102363)
53. Tziakas DN, Chalikias GK, Kaski JC (2005) Epidemiology of the diabetic heart. Coron Artery Dis 16(Suppl 1):S3-S10. doi: 10.1097/00019501-200511001- 00002 (Pubitemid 44365927)
54. Volz HC, Seidel C, Laohachewin D, Kaya Z, Muller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105:805-820. doi:10.1007/s00395-010-0114-3
55. Walker CA, Spinale FG (1999) The structure and function of the cardiac myocyte: a review of fundamental concepts. J Thorac Cardiovasc Surg 118:375-382. doi:10.1016/S0022-5223(99)70233-3 (Pubitemid 29360345)
56. Wang R, Li QF, Anfinogenova Y, Tang DD (2007) Dissociation of Crk-associated substrate from the vimentin network is regulated by p21-activated kinase on ACh activation of airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 292:L240-L248. doi:10.1152/ajplung.00199.2006 (Pubitemid 46103448)
57. Wang X, Li Q, Adhikari N, Hall JL (2006) A role for muscle LIM protein (MLP) in vascular remodeling. J Mol Cell Cardiol 40:503-509. doi:10.1016/j.yjmcc.2006.01.005
58. Watts GF, Chew KK, Stuckey BG (2007) The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med 4:263-273. doi: 10.1038/ncpcardio0861 (Pubitemid 46672115)
59. Xi L, Zhu SG, Hobbs DC, Kukreja RC (2011) Identification of protein targets underlying dietary nitrate-induced otection against doxorubicin cardiotoxicity. J Cell Mol Med 15:2512-2524. doi:10.1111/j.1582-4934.2011.01257. x
60. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y (2011) The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 106:925-952. doi: 10.1007/s00395-011-0216-6
61. Zhang H, Dellsperger KC, Zhang C (2012) The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol 107:1-11. doi:10.1007/ s00395-011-0237-1
62. Zhu SG, Xi L, Kukreja RC (2011) Type 2 diabetic obese db/db mice are refractory to myocardial ischemic postconditioning in vivo: potential role for Hsp20, F1-ATPase d, and Echs1. J Cell Mol Med doi:10.1111/j.1582-4934.2011. 01376.